Lilly invests heavily in UK

- Last updated on GMT

Related tags: Growth hormone, Eli lilly

US pharmaceutical major Eli Lilly has earmarked a hefty £220
million (€304 million) investment over the next four years in its
UK facilities, representing the largest investment by the firm in
any European country.

US pharmaceutical major Eli Lilly has earmarked a hefty £220 million (€304 million) investment over the next four years in its UK facilities, representing the largest investment by the firm in any European country.

The investment package includes a €38 million expansion of Lilly's manufacturing capabilities for Humatrope (somatropin), a treatment for growth hormone deficiency, at the firm's facilities in Liverpool. Currently, these are the largest bulk biotechnology manufacturing facilities in the UK.

Another major portion of the package is an approximately €55 million investment to create a European Centre for Excellence in Neuroscience Research at Erl Wood in south-east England. At least 120 scientists will be recruited to work at the unit over the next five years.

Lilly already employs more than 3,000 people in the UK and sees its operations there as a key contributor to future growth, according to Rich Pilnik, president of the firm's European operations.

Related topics: Markets & Regulations, Regulations

Related news

Related product

Multiple Sclerosis Analytical Report

Multiple Sclerosis Analytical Report

PatSnap | 15-Jun-2022 | Technical / White Paper

More than 2.3 million people are living with MS worldwide. Although there is no cure, new research and innovative treatments are continuously emerging....

Related suppliers

Follow us

Products

View more

Webinars